Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of inhaled flecainide for rapid cardioversion of recent-onset symptomatic atrial fibrillation
NL-OMON54054Phase 3Completed
- Sponsor
- InCarda Therapeutics
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of flecainide in Atrial fibrillation (AFib) (2 arms), sponsored by InCarda Therapeutics. Primary endpoint: Time to conversion of atrial fibrillation to sinus rhythm within 90 minutes. Started Sep 2022; status: completed.
02
Drugs
flecainide
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON54054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54054.